These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33032923)

  • 1. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer.
    Aoki S; Mizuma M; Hayashi H; Yoshimachi S; Hata T; Miura T; Takadate T; Maeda S; Ariake K; Kawaguchi K; Masuda K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Motoi F; Unno M
    Pancreatology; 2020 Dec; 20(8):1711-1717. PubMed ID: 33032923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of peritoneal cytology in potentially resectable pancreatic cancer.
    Yamada S; Fujii T; Kanda M; Sugimoto H; Nomoto S; Takeda S; Nakao A; Kodera Y
    Br J Surg; 2013 Dec; 100(13):1791-6. PubMed ID: 24227366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status.
    Sakoda T; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    J Gastrointest Surg; 2021 Nov; 25(11):2871-2880. PubMed ID: 33768425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
    Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.
    Yamada S; Takeda S; Fujii T; Nomoto S; Kanazumi N; Sugimoto H; Kasuya H; Kodera Y; Nagasaka T; Morita S; Nakao A
    Ann Surg; 2007 Aug; 246(2):254-8. PubMed ID: 17667504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection following preoperative chemoradiotherapy.
    Yuge T; Murata Y; Noguchi D; Ito T; Hayasaki A; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Mizuno S
    PLoS One; 2024; 19(9):e0309834. PubMed ID: 39240836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology.
    Ohgi K; Sugiura T; Okamura Y; Ashida R; Yamada M; Otsuka S; Todaka A; Uesaka K
    Langenbecks Arch Surg; 2023 Apr; 408(1):165. PubMed ID: 37103587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer.
    Yoshioka R; Saiura A; Koga R; Arita J; Takemura N; Ono Y; Yamamoto J; Yamaguchi T
    World J Surg; 2012 Sep; 36(9):2187-91. PubMed ID: 22555286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
    Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
    Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer.
    Tanemura M; Furukawa K; Mikamori M; Asaoka T; Yasuoka H; Marukawa D; Urata Y; Yamada D; Kobayashi S; Eguchi H
    Sci Rep; 2024 May; 14(1):10199. PubMed ID: 38702437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
    Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
    World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
    Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
    Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
    Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
    Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas.
    Meszoely IM; Lee JS; Watson JC; Meyers M; Wang H; Hoffman JP
    Am Surg; 2004 Mar; 70(3):208-13; discussion 213-4. PubMed ID: 15055843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy.
    Aoyama T; Atsumi Y; Kazama K; Murakawa M; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1129-S1134. PubMed ID: 30539858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
    Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
    Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.